Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial
Por:
Balari, AS, Khan, AM, Oriol, A, Mesa, MG, Anwer, F, Rodríguez, CE, Lipe, B, Rodríguez-Otero, P, Amatangelo, M, Jin, KX, Solomon, T, Taningco, L, Amin, A, Maciag, P and Lonial, S
Publicada:
1 sep 2025
Resumen:
Filiaciones:
Balari, AS:
Univ Barcelona, Inst Catala Oncol Hosp, Hematol Dept, IDIBELL, Barcelona, Spain
Khan, AM:
Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA
:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
Mesa, MG:
Vall dHebron Hosp, Hematol Dept, Barcelona, Spain
Anwer, F:
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA
Rodríguez, CE:
Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain
Lipe, B:
UR Med, Dept Med, Rochester, NY USA
Rodríguez-Otero, P:
Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
Amatangelo, M:
Bristol Myers Squibb, Princeton, NJ USA
Jin, KX:
Bristol Myers Squibb, Princeton, NJ USA
Solomon, T:
Bristol Myers Squibb, Princeton, NJ USA
Taningco, L:
Bristol Myers Squibb, Princeton, NJ USA
Amin, A:
Bristol Myers Squibb, Princeton, NJ USA
Maciag, P:
Bristol Myers Squibb, Princeton, NJ USA
Lonial, S:
Emory Univ, Winship Canc Inst, Atlanta, GA USA
Ohio State Univ, Solove Res Inst, Comprehens Canc Ctr, Columbus, OH USA
|